Axsome Therapeutics announced today it is joining the migraine advocacy community to raise awareness of unmet patient needs during Migraine & Headache Awareness Month this June.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month
- Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month
- Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024
- Axsome Therapeutics to Present at Upcoming Investor Conferences
- Axsome Therapeutics price target lowered to $106 from $109 at Mizuho
Questions or Comments about the article? Write to editor@tipranks.com